<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02231788</url>
  </required_header>
  <id_info>
    <org_study_id>330HT13010</org_study_id>
    <nct_id>NCT02231788</nct_id>
  </id_info>
  <brief_title>The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy</brief_title>
  <acronym>TENUVA-BP</acronym>
  <official_title>A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial to Evaluate the Efficacy of Telmisartan/S-Amlodipine(Telminuvo® Tab. 40/2.5mg) on 24-hour Ambulatory BP Control Compared With Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Efficacy of a Fixed Dose Combination of Telmisartan/S-Amlodipine on 24-hour Ambulatory BP
      Control Compared with Telmisartan Monotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, Prospective, Randomized, Open-label, Phase 4 Trial designed to Evaluate the
      Efficacy of a Fixed Dose Combination of Telmisartan/S-Amlodipine on 24-hour Ambulatory BP
      Control Compared with Telmisartan Monotherapy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the 24hr mean blood pressure by ambulatory blood pressure monitoring(ABPM) at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 24hr mean daytime, nighttime, morning blood pressure by ABPM at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Each timepoint is as following:
Daytime: 06:00~21:59
Nighttime: 22:00~05:59
Morning: 06:00~11:59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the clinic mean blood pressure at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24hr ABPM and Clinic BP control at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>&lt;24hr ABPM&gt;
24hr mean BP: 24hr mean Systolic blood pressure(SBP)&lt;130mmHg and 24hr mean Diastolic blood pressure(DBP)&lt;80mmHg
Daytime BP: Daytime mean SBP&lt;135mmHg and Daytime mean DBP&lt;85mmHg
Night time BP: Night time mean SBP&lt;120mmHg and Night time mean DBP&lt;70mmHg
&lt;Clinic BP&gt;
: Mean sitting systolic blood pressure(MSSBP)&lt;140mmHg and Mean sitting diastolic blood pressure(MSDBP)&lt;90mmHg (If Hypertension with Diabetes mellitus or Chronic kidney disease: MSSBP&lt;130mmHg and MSDBP&lt;80mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24hr ABPM and Clinic BP response at week 8.</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>&lt;24hr ABPM&gt; 24hr mean SBP and DBP reduction≥10mmHg
&lt;Clinic BP&gt; MSSBP and MSDBP≥10mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telminuvo®Tab. 40/2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmitrend®Tab. 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmitrend®Tab.(Telmisartan) 80mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telminuvo®Tab. 40/2.5mg</intervention_name>
    <description>Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg</description>
    <arm_group_label>Telminuvo®Tab. 40/2.5mg</arm_group_label>
    <other_name>Telmisartan/S-Amlodipine 40/2.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmitrend®Tab. 80mg</intervention_name>
    <description>Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg</description>
    <arm_group_label>Telmitrend®Tab. 80mg</arm_group_label>
    <other_name>Telmisartan 80mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than 19 years in hypertension patient

          2. Hypertension is satisfied with the Clinic blood pressure that was measured at the time
             of randomization

               -  Clinic MSSBP ≥ 140mmHg

               -  Clinic MSSBP ≥ 130mmHg in diabetes mellitus or chronic kidney disease

                    -  Diabetes mellitus

                         -  Before screening, diagnosed with diabetes mellitus being treated with
                            oral hypoglycemic agents at least 30 days OR

                         -  Patients who meet the following results of laboratory tests at the time
                            of randomization. : Fasting plasma glucose ≥ 126mg/dL

                    -  Chronic kidney disease

                         -  Patients who meet the following results of laboratory tests at the time
                            of randomization.: 15mL/min/1.73m2 ≤ estimated glomerular filtration
                            rate ≤ 60mL/min/1.73m2

          3. Patient who decided to participate and signed on an informed consent form willingly

        Exclusion Criteria:

          1. Clinic MSSBP ≥ 200mmHg or Clinic MSDBP ≥ 120mmHg at the time of Screening and
             Randomization

          2. As night workers who sleep during the day and whose working hours including 00:00 to
             04:00

          3. Abnormal laboratory test results

               -  Aspartate aminotransferase/Alanine aminotransferase &gt; Upper normal limit X 3

               -  Serum creatinine &gt; Upper normal limit X 4

          4. Secondary hypertension patient without diabetes mellitus, chronic kidney disease:
             coarctation of aorta, cushing's syndrome, pheochromocytoma, primary aldosteronism etc.

          5. Severe heart disease(Heart failure; New York Heart Association(NYHA) class 3, 4) and
             recent unstable angina or myocardial infarction or valvular heart disease or
             arrhythmia requiring treatment within the past 3 months

          6. Severe cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage
             within 6 months

          7. Patient who is planning for a renal transplantation during the trial

          8. Severe or malignant retinopathy

          9. Acute of chronic inflammatory status requiring treatment

         10. A history of cancer within five years

         11. A history of angioedema with ACE inhibitors or angiotensin-Ⅱ receptor blockers

         12. Severe hypersensitivity to amlodipine or telmisartan

         13. Surgical or medical conditions

               -  History of major gastrointestinal surgery

               -  History of active inflammatory bowel syndrome within 12 months

               -  Abnormal pancreatic functions

               -  Gastrointestinal/rectal bleeding

               -  Urinary tract obstruction

         14. Need for other antihypertensive drugs during the trial

         15. Need for prohibited medication specified in the protocol

         16. Administration of other Investigational Product within 30 days

         17. History of drug or alcohol abuse within 6 months

         18. Pregnant, breast-feeding and childbearing age who don't use adequate contraception

         19. Another clinical condition in investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Soo Kim, Professor</last_name>
    <phone>+82-10-8393-2424</phone>
    <email>usahyosoo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Ansan-si</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Yeop Lim, Professor</last_name>
      <phone>+82-31-412-5366</phone>
      <email>vnlover@daum.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <state>Aran</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Jae Joo, Professor</last_name>
      <phone>+82-64-717-1701</phone>
      <email>sejjoo@jejunu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-Jae Joo, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Bundang-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Uk Lim, Professor</last_name>
      <phone>+82-31-780-5852</phone>
      <email>swlim@cha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang-Uk Lim, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Bundang-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Hwan Yoon, Professor</last_name>
      <phone>+82-31-787-7032</phone>
      <email>Kunson2@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Chang-Hwan Yoon, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Bae Kim, Professor</last_name>
      <phone>+82-2-958-8176</phone>
      <email>jinbbai@khu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jin-Bae Kim, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeok-Mun Kwon, Professor</last_name>
      <phone>+82-2-2019-3310</phone>
      <email>kwonhm@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hyeok-Mun Kwon, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumi cha Hospital</name>
      <address>
        <city>Gumi</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeon-Sang Lee, Professor</last_name>
      <phone>+82-54-450-9551</phone>
      <email>phd75602002@daum.net</email>
    </contact>
    <investigator>
      <last_name>Hyeon-Sang Lee, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongro-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Soo Kim, Professor</last_name>
      <phone>+82-10-8393-2424</phone>
      <email>usahyosoo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyo-Soo Kim, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Jung-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Min Choi, Professor</last_name>
      <phone>+82-2-2260-7565</phone>
      <email>choichoism@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Seun-Min Choi, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyoung Im Cho, Professor</last_name>
      <phone>+82-51-990-6105</phone>
      <email>kyoungim74@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sejong Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Wonmi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeong-Jin Choi, Professor</last_name>
      <phone>+82-32-340-1433</phone>
      <email>cyjheart@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yeong-Jin Choi, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hosipital</name>
      <address>
        <city>Seoul</city>
        <state>Yeongdeungpo-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nam-Ho Lee, Professor</last_name>
      <phone>+82-2-829-5395</phone>
      <email>Namholee2@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Nam-Ho Lee, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2014</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Telminuvo</keyword>
  <keyword>Telmitrend</keyword>
  <keyword>Hypertension</keyword>
  <keyword>24hr ABPM</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>S-amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

